Anti-secretory and anti-proliferative actions of next-generation dual subtype 2 and 5 somatostatin receptor ligands in neuroendocrine tumor models

IntroductionFirst-generation somatostatin receptor ligands (SRLs) mainly target SSTR2, whereas neuroendocrine tumors (NETs) often express multiple SSTR subtypes, frequently SSTR5. Dual SSTR2/SSTR5 targeting may enhance anti-hormonal and antiproliferative effects. We evaluated five novel dual SSTR2/S...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Francesco Fedeli, Margarita Bistika, Francesco Ascione, Alessandro Marangelo, Fabio L. Guzzi, Jörg Schrader, Alan G. Harris, Natalia S. Pellegata
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Frontiers Media S.A. 2026-02-01
Rangatū:	Frontiers in Oncology
Ngā marau:	acromegaly pancreatic NETs pituitary adenomas somatostatin receptor ligands (SRLs) somatostatin receptors (SSTRs)
Urunga tuihono:	https://www.frontiersin.org/articles/10.3389/fonc.2026.1766563/full
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!